Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
Status:
Active, not recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This is A Randomized, Blinded, Placebo- and Positive-Controlled, Four-Period,
Crossover-Design Thorough QT/QTc (TQT) Study to Evaluate the Effect of Orelabrutinib on
Cardiac Repolarization in Healthy Subjects
Phase:
Phase 1
Details
Lead Sponsor:
Beijing InnoCare Pharma Tech Co., Ltd.
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination